Trial record 1 of 1 for:
VRDN-001-101
A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05176639 |
|
Recruitment Status :
Recruiting
First Posted : January 4, 2022
Last Update Posted : January 26, 2023
|
Sponsor:
Viridian Therapeutics, Inc.
Information provided by (Responsible Party):
Viridian Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). This clinical trial will evaluate the safety, tolerability and pharmacokinetics (the concentration of drug in the blood over time) of VRDN-001 in healthy volunteers and in patients with TED. Study participants with TED will also be evaluated over time for changes in their signs and symptoms of TED compared to their baseline measurements.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Thyroid Eye Disease | Drug: VRDN-001 Drug: Placebo | Phase 2 Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 184 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED) |
| Actual Study Start Date : | December 3, 2021 |
| Estimated Primary Completion Date : | June 2023 |
| Estimated Study Completion Date : | December 2023 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Phase 1/2 MAD (HV and TED)
Healthy participants and participants with TED will be randomized to receive two intravenous infusions of VRDN-001 or placebo with an interval of 3 weeks.
|
Drug: VRDN-001
Multiple ascending doses of VRDN-001, ranging from 3 mg/kg to 20 mg/kg Drug: Placebo Multiple doses of placebo |
|
Experimental: Phase 2/3 extension study
Participants with TED will be randomized to one of two VRDN-001 dosing regimens or placebo. The dosing regimens may include doses up to 20 mg/kg with the dosing interval and duration to be defined based on the results of the MAD study part.
|
Drug: VRDN-001
Multiple doses of VRDN-001 using dosing regimen 1 Drug: VRDN-001 Multiple doses of VRDN-001 using dosing regimen 2 Drug: Placebo Multiple doses of placebo |
Primary Outcome Measures :
- Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0 [ Time Frame: Up to Day 50 for MAD healthy volunteers, up to Day 169 for MAD TED subjects, and up to Week 52 for extension study subjects ]
- Proptosis responder rate [ Time Frame: Up to Week 12 for MAD TED subjects, and up to Week 24 for extension study subjects ]Proportion of TED subjects with a reduction of proptosis of ≥ 2 mm from baseline
Secondary Outcome Measures :
- Change from baseline in measurement of proptosis as determined by exophthalmometer [ Time Frame: Up to Week 12 for MAD TED subjects, and up to Week 52 for extension study subjects ]
- Change from baseline in volume of orbital fat as determined by MRI [ Time Frame: Up to Week 12 for MAD TED subjects, and up to Week 52 for extension study subjects ]
- Change from baseline in volume of extraocular muscles as determined by MRI [ Time Frame: Up to Week 12 for MAD TED subjects, and up to Week 52 for extension study subjects ]
- Change from baseline in facial fat volume as determined by MRI [ Time Frame: Up to Week 12 for MAD TED subjects, and up to Week 52 for extension study subjects ]
- Change from baseline in Clinical Activity Score (CAS) [ Time Frame: Up to Week 12 for MAD TED subjects, and up to Week 52 for extension study subjects ]Each of 7 clinical signs and symptoms of ocular inflammation is scored as present or absent (score of 1 or 0, respectively). The CAS is the sum of the individual scores (range from 0 to 7) where a higher score indicates a greater level of inflammation.
- Change from baseline in Subjective Diplopia Score [ Time Frame: Up to Week 12 for MAD TED subjects, and up to Week 52 for extension study subjects ]Diplopia grade is assessed using the Gorman Subjective Diplopia Score (range from 0 to 3) based on verbal responses by the study subject. A higher score indicates a worse diplopia grade.
- Change from baseline in Graves Orbitopathy-Quality of Life (GO-QoL) combined score [ Time Frame: Up to Week 12 for MAD TED subjects, and up to Week 52 for extension study subjects ]
Other Outcome Measures:
- VRDN-001 concentrations in the blood over time [ Time Frame: Up to Day 50 for MAD subjects and up to Week 25 for extension study subjects ]
- Incidence of anti-drug antibody (ADA) development in VRDN-001-treated subjects over time [ Time Frame: Up to Day 50 for MAD subjects and up to Week 25 for extension study subjects ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Key Inclusion Criteria for Healthy Volunteers:
- Must be free of clinically significant disease or medical conditions as determined by the Investigator
- Female volunteers must not be of child-bearing potential
Key Exclusion Criteria for Healthy Volunteers:
• Must not have a history of or any evidence of diabetes mellitus, recently diagnosed renal impairment or inflammatory bowel disease, or clinically significant ear pathology or hearing impairment
Key Inclusion Criteria for Participants with TED:
- Must have moderate to severe active TED with documented evidence of ocular symptoms or signs that began within 1 year prior to screening
- Must have Clinical Activity Score (CAS) of ≥ 4 on the 7-item scale for the study (more proptotic) eye
- Must agree to use highly effective contraception as specified in the protocol
- Female TED participants must have a negative serum pregnancy test
Key Exclusion Criteria for Participants with TED:
- Must not have received prior treatment with another anti-IGF-1R monoclonal antibody
- Must not have used oral corticosteroids within 4 weeks prior to Day 1
- Must not have received rituximab, tocilizumab or other immunosuppressive agents within 90 days prior to Day 1
- Must not have evidence of optic nerve involvement within the previous 6 months
- Must not have corneal decompensation in the study eye unresponsive to medical management
- Must not have had previous orbital irradiation or surgery for TED in the study eye
- Must not have a history inflammatory bowel disease, or clinically significant ear pathology or hearing impairment
- Must not have received an investigational agent for any condition within 60 days
- Female TED participants must not be pregnant or lactating
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05176639
Contacts
| Contact: VP, Clinical Operations | 617-272-4609 | viridian-clinical-trials@viridiantherapeutics.com |
Locations
Show 20 study locations
Sponsors and Collaborators
Viridian Therapeutics, Inc.
Investigators
| Study Director: | Barrett Katz, MD, MBA | Viridian Therapeutics, Inc. |
| Responsible Party: | Viridian Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT05176639 |
| Other Study ID Numbers: |
VRDN-001-101 |
| First Posted: | January 4, 2022 Key Record Dates |
| Last Update Posted: | January 26, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Viridian Therapeutics, Inc.:
|
Graves Ophthalmopathy Thyroid Eye Disease Thyroid-Associated Ophthalmopathy Dysthyroid Ophthalmopathy Graves Eye Disease |
Graves Orbitopathy Myopathic Ophthalmopathy Congestive Ophthalmopathy Edematous Ophthalmopathy Infiltrative Ophthalmopathy |
Additional relevant MeSH terms:
|
Eye Diseases Graves Ophthalmopathy Thyroid Diseases Endocrine System Diseases Eye Diseases, Hereditary Graves Disease Exophthalmos |
Orbital Diseases Genetic Diseases, Inborn Goiter Hyperthyroidism Autoimmune Diseases Immune System Diseases |